Glaxo's HIV drug a step closer to regulatory submission
Pharmaceuticals behemoth GlaxoSmithKline said its joint venture company, Shionogi-ViiV Healthcare, has completed an initial clinical registration package for dolutegravir, its treatment for HIV patients.
Pharmaceuticals behemoth GlaxoSmithKline said its joint venture company, Shionogi-ViiV Healthcare, has completed an initial clinical registration package for dolutegravir, its treatment for HIV patients.
Phase III data required for initial regulatory filings for dolutegravir to be used on adults infected with HIV are now in house. Data from the two phase III studies in treatment-experienced patients (VIKING-3 and SAILING) will be the subject of future presentations at scientific meetings, Glaxo revealed.
Together with previously disclosed data from the SPRING-2 and SINGLE studies, which were conducted on patients who previously had not been treated for HIV, the latest results support Shionogi-ViiV Healthcare's plans to commence global regulatory submissions for dolutegravir before the end of 2012.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dolutegravir is not yet approved as a treatment for HIV or any other indication anywhere in the world.
The Shionogi-ViiV Healthcare joint venture was established between Shionogi,the Japanese pharmaceutical firm, ViiV Healthcare, a global company with a sole focus on HIV established in 2009 by Glaxo and US peer Pfizer.
Dolutegravir is the joint venture's flagship development drug but the company is also developing another integrase inhibitor - drugs which interfere with the role the enzyme integrase plays in HIV replication - which is at an earlier stage of development.
JH
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Government launches full review of parental leave and pay – what could it mean for you?
The government wants parental leave to be fairer - will its shake-up fix the widespread problem for families?
-
Nationwide: House prices see biggest monthly fall in over two years
UK house prices dropped by 0.8% in June, according to Nationwide. We reveal the top-performing and worst-performing regions